BEAM Beam Therapeutics Inc

$BEAM reported earnings this morning before the open and missed EPS estimates with a larger loss: -$1.28 GAAP EPS vs -$1.15 expected, according to Stock Meadow.

📅 CATALYST REMINDER | $BEAM October 27–28, 2026 — Phase 1/2 Data Discussion / Poster Beam will host a BEAM-301 investor webcast on October 27 and present initial Phase 1/2 data for glycogen storage disease type Ia at ESGCT on October 28. More details in our hub. #BEAM #Biotech #GeneEditing

H.C. Wainwright says the $BEAM (Buy-$80) BEAM-301 data presented today at the ESGCT congress strengthens its conviction in the platform's pot'l across hematology and liver-targeted genetic diseases — sees higher PoS for both BEAM-302 and BEAM-301 — for '301, the early fasting and starch-reduction findings are encouraging.

$BEAM Is a 2-of-3 response at 40 mg enough to carry Beam's BEAM-301 to the FDA? 🏢 Beam Therapeutics, a gene-editing biotech worth about $2.46B on its $23.79 close at 16:00 ET on Oct 26, 2026, said Oct 27 that the third patient on BEAM-301's highest dose tested so far, 40 mg, for the blood-sugar disorder GSDIa showed no rise in fasting time at the first post-dose check (data to Aug 17, 2026) ⚠️ Four of six patients had serious treatment-related side effects, including three Grade 3 infusion reactions, so the 60 mg cohort also tests Beam's changed steroid premedication and infusion rate 📈 On the bull side, median follow-up is now 7.6 months, glucose control improved despite less starch, and Beam plans to engage the FDA on a potential path to approval 📅 Next: Investor webcast Oct 27, 2026, at 8:00 a.m. ET; 60 mg enrollment is underway with no data date given Source: GlobeNewswire release, Oct 27 + SEC 8-K, Aug 4

$BEAM 🏥 ECM Therapeutics, Inc. announced interim clinical results suggesting its extracellular matrix hydrogel ECMT-100 could meaningfully improve treatment for patients with anorectal fistulas. Prioritized by relevance

$BEAM (Beam Therapeutics, gene-editing biotech): in first BEAM-301 data in blood-sugar disorder GSDIa, both evaluable 40 mg patients hit the ≥15-hour fasting maximum by Day 36, vs a 2.5-hour median baseline, and cut daily starch 71% and 92%. A ~$2.68B company (Oct 9 close $25.71) with $1.2B in cash and marketable securities as of June 30, 2026 (Q2 net loss $122.7M); runway to mid-2029 with a planned $200M debt draw. But: n=2, 53-day median follow-up; 20 mg median only 2.9→4.3 hrs; 3 Grade 3 infusion reactions. Webcast Oct 27, ESGCT poster Oct 28.

BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside $BEAM $ARKK $XBI https://stocktwits.com/news/equity/markets/beam-stock-climbs-on-first-look-at-one-time-gsd-ia-gene-fix-h-c-wainwright-sees-further-200-upside/cZUe1MhRBCD

$BEAM — First BEAM-301 data in GSD Ia: genetic correction proof of concept; FDA pathway discussion started. 4 of 6 patients had serious related events. Information only — not investment advice. More details in our hub.